Who founded Immuneering?

Immuneering was founded by Benjamin J. Zeskind in 2008.

Who are Immuneering's investors?

Immuneering's investors include Rock Springs Capital, T. Rowe Price.

How much funding has Immuneering raised?

Immuneering has disclosed $82.2M raised across 3 rounds.

Where is Immuneering headquartered?

Immuneering is headquartered in Cambridge, US.

Immuneering

NASDAQ: IMRX

Cambridge, US · Founded 2008 · Delaware corporation · 63 employees on LinkedIn · 3 known investors

Find your way into Immuneering

2,064 people in our graph share verified history with the Immuneering team — schools, employers, funds. One of them is your warm intro.

Hiroshi Tamadaunlockedknows Leah R. Neufeld · together at Luzsana Biotechnology (overlapped)

×11knows the team · via Latham & Watkins

Immuneering develops Deep Cyclic Inhibitors, a class of oncology medicines designed to pulse dosing faster than cancer's adaptive mechanisms to limit resistance and reduce side effects. The company targets more durable tumor control and improved tolerability for cancer patients.

Biotech Healthtech

Founders & leadership

Immuneering was founded in 2008 by Benjamin J. Zeskind.

Benjamin J. ZeskindFounder

Harold E. Brakewood Chief Business OfficerHarold E. Brakewood is Chief Business Officer at Immuneering, which develops oncology medicines designed to improve tumor control and tolerability in cancer patients. His background includes C-suite leadership roles focused on business development and commercialization across oncology, rare diseases, and other therapeutic areas.

Brett Hall CSOBrett Hall serves as Chief Scientific Officer of Immuneering, which develops Deep Cyclic Inhibitors for oncology treatment. He brings drug discovery and development experience across immunology and oncology, including preclinical and clinical pharmacology and biomarker development.

Michael D. Bookman Chief Legal Officer & SecretaryChief Legal Officer and Secretary at Immuneering, which develops oncology medicines. Experienced in business and startup advisory.

Igor MatushanskyChief Medical Officer

Mallory Morales SVP Finance and Chief Accounting OfficerMallory Morales is a CPA and senior finance executive with 20 years of experience in high-growth organizations, including roles ranging from startups to multi-billion-dollar enterprises. Her expertise spans corporate finance, capital markets, governance and compliance, and process transformation, with experience in financial reporting, treasury management, IPOs, M&A, and SEC compliance.

Leah R. Neufeld Chief People OfficerLeah R. Neufeld is Chief People Officer at Immuneering, an oncology biotech company. She brings human resources experience across large pharmaceutical and biotech organizations, with background spanning oncology, neurology, cardiology, gene therapy, and manufacturing operations.

Joseph KekstNamed on SEC filing

Board

Peter FeinbergBoard director

Laurie B. KeatingBoard director

Robert CarpenterBoard director

Thomas J. SchallBoard director

Investors · 3

Rock Springs CapitalreportedBaltimore

How we know: the S-1 prospectus · Not right? Tell us

T. Rowe PricereportedBaltimore

How we know: the S-1 prospectus · Not right? Tell us

Also in the syndicate · 1

Boxcar PMJ LLClead

Reported raises · per SEC filings

Form D private placements

$82.2M disclosed across 3 rounds · 2020–2025

▶$25MraisedSep 2025 · 9 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Benjamin J. ZeskindExecutive Officer, Director
Laurie B. KeatingDirector
Robert CarpenterDirector
Thomas J. SchallDirector
Diana F. HausmanDirector
Peter FeinbergDirector

Offering amount: $25M
Amount sold: $25M
First sale: Aug 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$37.2MraisedJan 2021 · 39 investors · Other

Rule 506(b)

Officers, directors & promoters on the filing

Benjamin J. ZeskindExecutive Officer, Director
Robert CarpenterDirector
Joseph KekstDirector
Andrew PhillipsDirector

Offering amount: $62M
Amount sold: $37.2M
First sale: Dec 2020
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$20MraisedJan 2020 · 67 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Robert CarpenterDirector
Benjamin J. ZeskindExecutive Officer, Director
Joseph KekstDirector

Offering amount: $20M
Amount sold: $20M
First sale: Jan 2020
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Bioworld83 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Immuneering for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Immuneering do?: Immuneering develops Deep Cyclic Inhibitors, a class of oncology medicines designed to pulse dosing faster than cancer's adaptive mechanisms to limit resistance and reduce side effects. The company targets more durable tumor control and improved tolerability for cancer patients.
Who founded Immuneering?: Immuneering was founded by Benjamin J. Zeskind in 2008.
Who are Immuneering's investors?: Immuneering's investors include Rock Springs Capital, T. Rowe Price.
How much funding has Immuneering raised?: Immuneering has disclosed $82.2M raised across 3 rounds.
Where is Immuneering headquartered?: Immuneering is headquartered in Cambridge, US.